Berenberg Bank Reaffirms "Buy" Rating for AstraZeneca (LON:AZN)

Berenberg Bank restated their buy rating on shares of AstraZeneca (LON:AZN - Free Report) in a research note issued to investors on Monday, MarketBeat Ratings reports. Berenberg Bank currently has a GBX 140 ($1.74) price target on the biopharmaceutical company's stock.

Other research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. restated an "overweight" rating and set a £140 ($173.87) price objective on shares of AstraZeneca in a report on Friday, November 22nd. Shore Capital reissued a "buy" rating on shares of AstraZeneca in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of GBX 7,935.67 ($98.56).

AstraZeneca Price Performance

Shares of AstraZeneca stock traded up GBX 63 ($0.78) during midday trading on Monday, hitting £113.77 ($141.29). 3,044,293 shares of the company traded hands, compared to its average volume of 40,437,469. The stock has a market cap of £176.34 billion, a price-to-earnings ratio of 3,611.75, a PEG ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 84.97, a quick ratio of 0.59 and a current ratio of 0.89. The firm's fifty day moving average price is £106.64 and its 200-day moving average price is £115.24. AstraZeneca has a 12 month low of GBX 9,461 ($117.50) and a 12 month high of £133.88 ($166.27).

Insider Buying and Selling at AstraZeneca

In other AstraZeneca news, insider Pascal Soriot bought 20,000 shares of the stock in a transaction that occurred on Thursday, November 14th. The shares were purchased at an average cost of £102.03 ($126.71) per share, for a total transaction of £2,040,600 ($2,534,277.20). Also, insider Tony Mok bought 1,500 shares of the firm's stock in a transaction dated Tuesday, November 19th. The stock was acquired at an average cost of £126.80 ($157.48) per share, with a total value of £190,200 ($236,214.61). Company insiders own 0.04% of the company's stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.